Comment on

• Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

  Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, Ewer MS, Bianchine JR, Gams RA. Swain SM, et al. J Clin Oncol. 1997 Apr;15(4):1318-32. doi: 10.1200/JCO.1997.15.4.1318. J Clin Oncol. 1997. PMID: 9193323 Clinical Trial.
• Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.

  Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, Gams RA. Swain SM, et al. J Clin Oncol. 1997 Apr;15(4):1333-40. doi: 10.1200/JCO.1997.15.4.1333. J Clin Oncol. 1997. PMID: 9193324 Clinical Trial.
• American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.

  Hensley ML, Schuchter LM, Lindley C, Meropol NJ, Cohen GI, Broder G, Gradishar WJ, Green DM, Langdon RJ Jr, Mitchell RB, Negrin R, Szatrowski TP, Thigpen JT, Von Hoff D, Wasserman TH, Winer EP, Pfister DG. Hensley ML, et al. J Clin Oncol. 1999 Oct;17(10):3333-55. doi: 10.1200/JCO.1999.17.10.3333. J Clin Oncol. 1999. PMID: 10506637
• Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.

  Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K, Tkaczuk K, Park YC, Lee LW. Batist G, et al. J Clin Oncol. 2001 Mar 1;19(5):1444-54. doi: 10.1200/JCO.2001.19.5.1444. J Clin Oncol. 2001. PMID: 11230490 Clinical Trial.